Biomarkers /
EGFL7
Overview
EGFL7 is altered in 0.50% of all cancers with colon adenocarcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in EGFL7 are EGFL7 Loss (0.10%), EGFL7 Amplification (0.08%), EGFL7 X212_splice (1.82%), EGFL7 S226L (0.01%), and EGFL7 A72T (0.01%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.